Vanguard Global Advisers
XBIT icon

Vanguard Global Advisers’s XBiotech XBIT Stock Holding History

Vanguard Global Advisers’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1K Hold
7,009
– – ﹤0.01% 3387
2026
Q1 		$16.5K Buy
+7,009
New +$17K ﹤0.01% 3371

Other funds holding XBIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Global Advisers's XBIT Position: Q2 2026 in Review

Vanguard Global Advisers held its XBiotech (XBIT) position steady in Q2 2026 at 7,009 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3387.

Vanguard Global Advisers first reported a position in XBIT in Q1 2026 and has held it in 2 quarters since. The position peaked at $16.5K in Q1 2026. 33 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.

  • Vanguard Global Advisers held 7,009 shares of XBiotech worth $16.1K as of Q2 2026.
  • Vanguard Global Advisers left its XBiotech share count unchanged in Q2 2026.
  • XBiotech made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3387 holding.
  • Vanguard Global Advisers first reported a position in XBiotech in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's XBiotech position peaked at $16.5K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.